The carbohydrate research activities of Seeberger are mainly focused on biomedical glycomics topics. To this end, he built up an integrated program bringing together chemists with biochemists and immunologists to quickly translate synthetic advances into biological insights. Realizing that rapid access to pure oligosaccharides, on a scale necessary for downstream studies, is one of the bottlenecks of glycan synthesis, he tackled head on the challenge to develop automated synthesis platforms following the example of instruments in operation for peptides and nucleotides for a long time. Prototypes of the instruments are now being evaluated in different laboratories. Using this approach compounds representing all classes of complex carbohydrates have been synthesized. Typical examples comprise glycosaminoglycan fragments, glycosyl phosphatidyl inositol anchors, and potential oligosaccharide-based conjugate vaccines. Several of the synthesized compounds are now in clinical trial. His laboratory was the first to print synthetic oligosaccharides onto chip surfaces using robotic array printers, of importance for the evaluation of carbohydrate-mediated interactions in health and disease. Other tools, such as carbohydrate-adorned metallodendrimers, polymers, and nanoparticles have found applications in carbohydrate detection and in vivo imaging. Seeberger has published over 250 papers, 2 edited books, and 24 book chapters, and over the years, he has received many honours, among others the Claude S. 
